418 related articles for article (PubMed ID: 35123422)
1. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P
Blood Cancer J; 2021 Jun; 11(6):106. PubMed ID: 34083504
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
8. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma.
Gu J; Liu J; Chen M; Huang B; Li J
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2568-2574. PubMed ID: 30142420
[TBL] [Abstract][Full Text] [Related]
12. Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real-world practice.
McMillan A; Tran TA; Galas-Filipowicz D; Camilleri M; Lecat C; Ainley L; Guo Y; Yong K; Sive J
Cytometry B Clin Cytom; 2023 Jul; 104(4):304-310. PubMed ID: 36370149
[TBL] [Abstract][Full Text] [Related]
13. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
14. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
15. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
16. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
18. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
19. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
